Shree Ganesh Bio

Which are the latest news on Shree Ganesh Bio?

Why is Shree Ganesh Biotech India Ltd falling/rising?

As of 05-Sep, Shree Ganesh Biotech India Ltd's stock price is currently at Rs. 0.49, reflecting a daily increase but a significant year-to-date decline of 20.97% and a one-year drop of 37.18%. Despite a slight rise today and increased investor participation, the stock continues to underperform compared to its sector and is trading below key moving averages.

As of 05-Sep, Shree Ganesh Biotech India Ltd's stock price is rising, currently at Rs. 0.49, reflecting a change of Rs. 0.01 or 2.08% increase. Despite this daily increase, the stock has shown a significant decline over longer periods, with a year-to-date drop of 20.97% and a one-year decline of 37.18%. <BR><BR>Today, the stock hit a new 52-week low of Rs. 0.48, indicating ongoing struggles. It has underperformed its sector by 6.7%, and is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. However, there has been a notable increase in investor participation, with delivery volume rising by 154.79% compared to the 5-day average, which may suggest some renewed interest in the stock despite its overall poor performance. <BR><BR>In contrast, the agriculture sector, where the company operates, has gained by 9.37%, highlighting a disconnect between the sector's performance and that of Shree Ganesh Biotech. Overall, while the stock is experiencing a slight rise today, the broader context indicates significant challenges and a trend of decline over time.

Who are in the management team of Shree Ganesh Bio?

The management team of Shree Ganesh Bio includes Aman Patel (Chairman & Wholetime Director), Kishan Nityanand Naidu, Harshad Rathod, Amrutaben Solanki (Directors), and independent directors Sombir Singh, Chandni Solanki, Nimeshkumar Parmar, along with Namita Acharya (Company Secretary & Compliance Officer). They oversee the company's operations and regulatory compliance.

The management team of Shree Ganesh Bio includes the following individuals:<BR><BR>1. **Aman Patel** - Chairman & Wholetime Director<BR>2. **Kishan Nityanand Naidu** - Director<BR>3. **Harshad Rathod** - Director<BR>4. **Amrutaben Solanki** - Director<BR>5. **Sombir Singh** - Independent Director<BR>6. **Chandni Solanki** - Independent Director<BR>7. **Nimeshkumar Parmar** - Independent Director<BR>8. **Namita Acharya** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and ensuring compliance with regulatory requirements.

What does Shree Ganesh Bio do?

Shree Ganesh Biotech India Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, incorporated in 1982. As of June 2026, it reported net sales of 1 Cr and a net profit of -1 Cr, with a market cap of INR 20 Cr.

Overview:<BR>Shree Ganesh Biotech India Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated on September 2, 1982, originally as 'S.P. Commercial Co. Limited'. It received the Certificate of Commencement of Business on September 14, 1982. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 20 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 43 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.12 <BR>Return on Equity: -0.61% <BR>Price to Book: 0.32<BR><BR>Contact Details:<BR>Address: 6 Flr Premises-602 Mahavir Apt, 2 Aushutosh Mukherjee Road Kolkata West Bengal : 700020 <BR>Email: shreeganeshbiotechindialtd@gmail.co <BR>Website: http://shreeganeshbiotech.tech/

Who are the peers of the Shree Ganesh Bio?

Shree Ganesh Bio's peers include Cian Healthcare, Welcure Drugs, Venmax Drugs, Ishita Drugs, Centuple Global, Colinz Labs, Bacil Pharma, Zenith Health, and Saroja Pharma In. In terms of performance, Cian Healthcare leads with a 1-year return of 252.28%, while Shree Ganesh Bio has a return of -35.06%.

Peers: The peers of Shree Ganesh Bio are Cian Healthcare, Welcure Drugs, Venmax Drugs, Ishita Drugs, Centuple Global, Colinz Labs, Bacil Pharma, Zenith Health, and Saroja Pharma In.<BR><BR>Quality Snapshot: Excellent management risk is observed at Centuple Global, while Average management risk is found at Welcure Drugs and Saroja Pharma In, and the rest have Below Average management risk. Growth is rated as Good for Centuple Global, Welcure Drugs, Ishita Drugs, Colinz Labs, and Zenith Health, while Below Average growth is noted for Cian Healthcare, Venmax Drugs, Ishita Drugs, Bacil Pharma, Saroja Pharma In, and the rest. In terms of Capital Structure, Good ratings are assigned to Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, and Zenith Health, while Below Average ratings are given to Cian Healthcare, Venmax Drugs, Bacil Pharma, Saroja Pharma In, and the rest.<BR><BR>Return Snapshot: Cian Healthcare has the highest 1-year return at 252.28%, while Welcure Drugs has the lowest at -72.73%. Shree Ganesh Bio's 1-year return of -35.06% is better than Welcure Drugs but worse than Cian Healthcare. Additionally, peers such as Venmax Drugs, Ishita Drugs, Centuple Global, Zenith Health, and Bacil Pharma have negative six-month returns.

How big is Shree Ganesh Bio?

As of 31st August, Shree Ganesh Biotech India Ltd has a market capitalization of 20.00 Cr and reported Net Sales of 5.02 Cr with a Net Profit loss of 0.39 Cr over the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds of 63.26 Cr and Total Assets of 63.49 Cr.

As of 31st August, Shree Ganesh Biotech India Ltd has a market capitalization of 20.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 5.02 Cr. However, it experienced a loss of 0.39 Cr in Net Profit during the same period.<BR><BR>The latest reporting period for the balance sheet is March 2025, showing Shareholder's Funds of 63.26 Cr and Total Assets of 63.49 Cr.

Are Shree Ganesh Biotech India Ltd latest results good or bad?

Shree Ganesh Biotech India Ltd's latest results are concerning, showing a slight sales growth of 3.62% but a drastic net profit decline of 272.73%, indicating weak financial health and operational instability. Overall, the company's outlook appears negative due to declining profitability and low investor interest.

Shree Ganesh Biotech India Ltd's latest results indicate a troubling financial situation. The company reported a modest growth in net sales of 3.62% year-over-year for the quarter ended June 2026, but this comes after a significant decline of 61.24% in the same quarter last year. Despite this slight improvement in sales, the standalone net profit has worsened dramatically, showing a decline of 272.73%, which raises serious concerns about profitability.<BR><BR>Overall, the company's financial performance is characterized by operational instability, with a negative operating margin of -62.24% in the latest quarter. This trend of declining profitability, coupled with a return on equity of only 0.80% and a one-year return of -30.38%, suggests that the company's financial health is quite weak. The absence of promoter holding and negligible institutional interest further complicates its outlook.<BR><BR>In summary, the latest results for Shree Ganesh Biotech are largely negative, reflecting ongoing challenges and raising significant concerns about its long-term viability.

Should I buy, sell or hold Shree Ganesh Biotech India Ltd?

When is the next results date for Shree Ganesh Biotech India Ltd?

The next results date for Shree Ganesh Biotech India Ltd is August 4, 2026.

The next results date for Shree Ganesh Biotech India Ltd is scheduled for August 4, 2026.

How has been the historical performance of Shree Ganesh Bio?

Shree Ganesh Bio has experienced a significant decline in financial performance, with net sales dropping from 62.45 Cr in March 2023 to 22.96 Cr by March 2025, and profit after tax decreasing from 2.53 Cr to 0.28 Cr during the same period. Additionally, cash flow from operating activities turned negative in March 2025, indicating operational challenges.

Answer:<BR>The historical performance of Shree Ganesh Bio shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Shree Ganesh Bio's net sales peaked in March 2023 at 62.45 Cr, but have since declined to 22.96 Cr by March 2025. The total operating income followed a similar trend, decreasing from 72.64 Cr in March 2022 to 22.96 Cr in March 2025. Raw material costs have also decreased, from 68.84 Cr in March 2022 to 22.64 Cr in March 2025. The company reported an operating profit (PBDIT) of 0.39 Cr in March 2025, down from 3.49 Cr in March 2022, indicating a decline in profitability. Profit after tax has also decreased significantly from 2.53 Cr in March 2022 to 0.28 Cr in March 2025. The total liabilities have decreased from 93.55 Cr in March 2022 to 63.49 Cr in March 2025, while total assets have similarly declined from 93.55 Cr to 63.49 Cr over the same period. The cash flow from operating activities turned negative in March 2025 at -10.00 Cr, contrasting with positive cash flows in previous years. Overall, the financial performance of Shree Ganesh Bio has shown a downward trend in sales, profits, and cash flow, reflecting challenges in its operational efficiency and market conditions.

Who are the top shareholders of the Shree Ganesh Bio?

The top shareholders of Shree Ganesh Bio are primarily individual investors, holding 95.24% of the shares, while one Foreign Institutional Investor and New Era Fund Limited each hold 1.42%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Shree Ganesh Bio include a significant portion of individual investors, who hold 95.24% of the shares. Among institutional investors, there is one Foreign Institutional Investor (FII) that holds 1.42% of the shares. The highest public shareholder is New Era Fund Limited, which also holds 1.42%. Notably, there are no pledged promoter holdings, and no mutual funds are currently invested in the company.

Is Shree Ganesh Bio overvalued or undervalued?

As of February 14, 2024, Shree Ganesh Bio is considered overvalued and risky, with a PE Ratio of 35.48, negative EV to EBIT, and a PEG Ratio of 0.00, reflecting operational challenges and a significant underperformance of -23.93% over the past year compared to a 7.61% gain in the Sensex.

As of 14 February 2024, the valuation grade for Shree Ganesh Bio has moved from expensive to risky, indicating a significant shift in perception regarding its financial health. The company is currently assessed as overvalued. Key ratios reflect this concern, with a PE Ratio of 35.48, an EV to EBIT of -33.78, and a Price to Book Value of 0.56, suggesting that the stock price is not justified by its earnings or asset value.<BR><BR>In comparison to peers, Shree Ganesh Bio's PE ratio stands out against industry benchmarks, while its negative EV to EBIT and EV to EBITDA ratios highlight operational challenges. Notably, the company has a PEG Ratio of 0.00, indicating no growth expectations, which further supports the overvaluation assessment. Over the past year, Shree Ganesh Bio has underperformed significantly, with a stock return of -23.93% compared to a 7.61% gain in the Sensex, reinforcing the notion that the stock may not be a sound investment at its current price.

What is the technical trend for Shree Ganesh Bio?

As of March 21, 2025, Shree Ganesh Bio's technical trend has shifted to a bearish stance with weak strength, indicated by bearish MACD, RSI, moving averages, and KST across multiple timeframes, while Bollinger Bands suggest a mildly bearish trend.

As of 21 March 2025, the technical trend for Shree Ganesh Bio has changed from mildly bearish to bearish. The current stance is bearish with a weak strength. Key indicators driving this include a bearish MACD on the weekly chart, a bearish RSI on the weekly chart, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on both the weekly and monthly charts, while Bollinger Bands indicate a mildly bearish trend on both weekly and monthly timeframes. The Dow Theory shows no trend on both weekly and monthly levels, further supporting the bearish outlook.

What is the bonus history of the Shree Ganesh Bio?

Shree Ganesh Bio issued a 1:1 bonus on April 27, 2022, with a record date of April 28, 2022, granting shareholders one additional share for each share owned.

Shree Ganesh Bio has a recent bonus history that includes a 1:1 bonus issue. This was announced with an ex-date of April 27, 2022, and the record date was April 28, 2022. This means that shareholders received one additional share for every share they owned as of the record date. If you have any more questions about the company or its financial activities, feel free to ask!

Has Shree Ganesh Bio declared dividend?

No Dividend History Available